Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Randomized, Controlled, Open-label, Phase III Study to Assess Efficacy and Safety of Libevitug Injection in Participants With Chronic Hepatitis Delta Virus Infection (D-clear Study)

NCT07499544 is registered in ClinicalTrials.gov with Huahui Health as lead sponsor.

NCT NCT07499544
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07499544 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Randomized, Controlled, Open-label, Phase III Study to Assess Efficacy and Safety of Libevitug Injection in Participants With Chronic Hepatitis Delta Virus Infection (D-clear Study)
Lead sponsor
Huahui Health
Phase
Phase 3
Overall status
Recruiting
Start date
April 22, 2026
Completion date
January 29, 2030
Enrollment
160 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

chronic hepatitis d infection